12-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of lifeTofersen also led to robust and sustained reductions
'VecTabs' developed using VectorY's proprietary platform show positive effect on key drivers of ALS pathology VectorY, a biotech company focusing on the development of innovative gene therapy approaches
VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies,